VYNE Therapeutics Investor Relations Material
Latest events
R&D Day 2023
VYNE Therapeutics
Q1 2025
8 May, 2025
Q4 2024
6 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from VYNE Therapeutics Inc
Access all reports
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing proprietary therapeutics for the treatment of immuno-inflammatory conditions. The company's product pipeline includes VYN201, a locally administered pan-BET inhibitor designed to address diseases involving multiple inflammatory cell signaling pathways with minimal systemic exposure. Additionally, VYNE is working on VYN202, a BD2-selective oral small molecule, and FMX114, a combination gel in clinical trials for atopic dermatitis. The company is headquartered in Bridgewater, New Jersey, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
VYNE
Country
🇺🇸 United States